Radiopharm Theranostics Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Public

  • Employees
  • 14

Employees

  • Stock Symbol
  • RAD

Stock Symbol

  • Investments
  • 2

Radiopharm Theranostics General Information

Description

Radiopharm Theranostics Ltd is a clinical-stage radiotherapeutics company focused on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. It develops and commercializes radiopharmaceutical platforms for therapeutic and diagnostic applications in precision oncology. The Company develops targeted and scientifically validated radiopharmaceutical technologies in pre-clinical and clinical stages. It has one reportable segment, being the research, development, and commercialization of health technologies. The Company operates in Australia and the United States, with maximum revenue from the United States.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Company Secretary, C - The CFO Solution Level 3
  • 62 Lygon Street
  • Carlton, New South Wales 3053
  • Australia
+61 (03)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
ASX
Vertical(s)
Corporate Office
  • Company Secretary, C - The CFO Solution Level 3
  • 62 Lygon Street
  • Carlton, New South Wales 3053
  • Australia
+61 (03)

Radiopharm Theranostics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Radiopharm Theranostics Stock Performance

As of 20-Nov-2026, Radiopharm Theranostics’s current market cap is $12.5M with 4.71B shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$12.5M 4.71B 7.29M -$0.01

Radiopharm Theranostics Financials Summary

As of 30-Jun-2026, Radiopharm Theranostics has a trailing 12-month revenue of $1.88M.

In Thousands,
USD
TTM 30-Jun-2026 FY 2026 30-Jun-2026 FY 2025 30-Jun-2025 FY 2024 30-Jun-2024
EV 31,654 31,654 8,957 10,447
Revenue 1,875 1,875 2,351 196
EBITDA (38,894) (38,894) (25,269) (30,967)
Net Income (38,580) (38,580) (24,808) (31,423)
Total Assets 41,383 41,383 56,489 48,149
Total Debt 17,737 17,737 20,966 20,768
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Radiopharm Theranostics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Radiopharm Theranostics‘s full profile, request access.

Request a free trial

Radiopharm Theranostics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Radiopharm Theranostics Ltd is a clinical-stage radiotherapeutics company focused on the development of radiopharmaceuti
Drug Discovery
Carlton, Australia
14 As of 2025

Boston, MA
 

Eveleigh, Australia
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Radiopharm Theranostics Competitors (2)

One of Radiopharm Theranostics’s 2 competitors is AdvanCell, a Venture Capital-Backed company based in Boston, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
AdvanCell Venture Capital-Backed Boston, MA
Clarity Pharmaceuticals Formerly VC-backed Eveleigh, Australia
You’re viewing 2 of 2 competitors. Get the full list »

Radiopharm Theranostics Patents

Radiopharm Theranostics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2026905961-A0 Dendrimer Pending 01-Jul-2026

Radiopharm Theranostics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Radiopharm Theranostics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Radiopharm Theranostics‘s full profile, request access.

Request a free trial

Radiopharm Theranostics Investments & Acquisitions (2)

Radiopharm Theranostics’s most recent deal was a Merger/Acquisition with Pharma15 for . The deal was made on 03-Mar-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Pharma15 03-Mar-2023 Merger/Acquisition Diagnostic Equipment
Radiopharm Ventures 13-Sep-2022 Joint Venture Drug Discovery
To view Radiopharm Theranostics’s complete investments and acquisitions history, request access »

Radiopharm Theranostics ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Healthcare

Industry

Rank

Percentile

Medical Services

Subindustry

Rank

Percentile

To view Radiopharm Theranostics’s complete esg history, request access »

Radiopharm Theranostics FAQs

  • When was Radiopharm Theranostics founded?

    Radiopharm Theranostics was founded in 2021.

  • Where is Radiopharm Theranostics headquartered?

    Radiopharm Theranostics is headquartered in Carlton, Australia.

  • What is the size of Radiopharm Theranostics?

    Radiopharm Theranostics has 14 total employees.

  • What industry is Radiopharm Theranostics in?

    Radiopharm Theranostics’s primary industry is Drug Discovery.

  • Is Radiopharm Theranostics a private or public company?

    Radiopharm Theranostics is a Public company.

  • What is Radiopharm Theranostics’s stock symbol?

    The ticker symbol for Radiopharm Theranostics is RAD.

  • What is the current market cap of Radiopharm Theranostics?

    The current market capitalization of Radiopharm Theranostics is $12.5M.

  • What is Radiopharm Theranostics’s current revenue?

    The trailing twelve month revenue for Radiopharm Theranostics is $1.88M.

  • Who are Radiopharm Theranostics’s competitors?

    AdvanCell and Clarity Pharmaceuticals are competitors of Radiopharm Theranostics.

  • What is Radiopharm Theranostics’s annual earnings per share (EPS)?

    Radiopharm Theranostics’s EPS for 12 months was -$0.01.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process